Muscle weakness (HP:0001324)
Reduced strength of muscles.
Synonyms: Muscle weakness, Muscular weakness
Comment: It is important clinical to distinguish between muscle weakness, fatigue, and asthenia. Fatigue describes the inability to continue performing a task after multiple repetitions; in contrast, a patient with primary weakness is unable to perform the first repetition of the task. Asthenia is a sense of weariness or exhaustion in the absence of muscle weakness. Conditions that result in intrinsic muscle weakness can be divided into several main categories: infectious, neurologic, endocrine, inflammatory, rheumatologic, genetic, metabolic, electrolyte-induced, or drug-induced.
Pubmed References: PMID:15832536
Cross References: MSH:D018908, SNOMEDCT_US:26544005, UMLS:C0151786
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Mannose type O-glycan biosynthesis | 1.586e-7 | 0.000001110 | 427.93 | 6700.13 |
| 2 | Viral myocarditis | 0.02960 | 0.05482 | 37.53 | 132.12 |
| 3 | Arrhythmogenic right ventricular cardiomyopathy | 0.03785 | 0.05482 | 29.11 | 95.32 |
| 4 | Taste transduction | 0.04219 | 0.05482 | 26.02 | 82.37 |
| 5 | Hypertrophic cardiomyopathy | 0.04411 | 0.05482 | 24.85 | 77.54 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | neuronal action potential (GO:0019228) | 2.480e-13 | 1.116e-11 | 1174.88 | 34101.37 |
| 2 | membrane depolarization during action potential (GO:0086010) | 6.190e-13 | 1.393e-11 | 950.90 | 26730.60 |
| 3 | membrane depolarization (GO:0051899) | 1.893e-12 | 2.839e-11 | 739.37 | 19957.87 |
| 4 | action potential (GO:0001508) | 1.145e-11 | 1.288e-10 | 498.75 | 12564.94 |
| 5 | sodium ion transmembrane transport (GO:0035725) | 3.433e-10 | 3.061e-9 | 242.78 | 5290.74 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | voltage-gated sodium channel activity (GO:0005248) | 2.480e-13 | 2.232e-12 | 1174.88 | 34101.37 |
| 2 | sodium channel activity (GO:0005272) | 4.712e-12 | 2.120e-11 | 604.76 | 15772.67 |
| 3 | actinin binding (GO:0042805) | 0.01045 | 0.02686 | 110.94 | 506.01 |
| 4 | alpha-actinin binding (GO:0051393) | 0.01194 | 0.02686 | 96.46 | 427.12 |
| 5 | acetylglucosaminyltransferase activity (GO:0008375) | 0.02375 | 0.03562 | 47.15 | 176.34 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | voltage-gated sodium channel complex (GO:0001518) | 5.833e-14 | 9.917e-13 | 1664.83 | 50731.79 |
| 2 | sodium channel complex (GO:0034706) | 5.000e-13 | 4.250e-12 | 998.50 | 28281.59 |
| 3 | axon (GO:0030424) | 2.123e-10 | 1.203e-9 | 149.94 | 3339.58 |
| 4 | neuron projection (GO:0043005) | 8.582e-8 | 3.647e-7 | 53.02 | 862.66 |
| 5 | integral component of Golgi membrane (GO:0030173) | 0.0003294 | 0.0009334 | 94.04 | 754.04 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| FKTN | – |
| FKRP | – |
| POMGNT1 | – |
| SCN4A | LEVOBUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE |
| SCN1A | ETHOSUXIMIDE |
| SCN2A | – |
| SCN8A | – |
| MYOT | – |
| SCN11A | – |
| SGCB | – |
